Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC ibuprofen brand owned by Haleon (LSE/NYSE: HLN, GSK 2022 spinoff); Pfizer exited $3B+ stake early 2025 with ADA Seal for Advil Dual Action dental pain competing with Tylenol and Aleve for OTC analgesic market.
Advil is a global over-the-counter ibuprofen pain relief brand — owned by Haleon plc (LSE: HLN / NYSE: HLN), the consumer healthcare company spun off from GSK on July 18, 2022, with Pfizer completing its full stake exit in early 2025 for $3+ billion — providing consumers with 23+ ibuprofen-based product varieties for pain, headache, cold, and sleep management including Advil Extra Strength, Advil Rapid Release Gels, Advil PM, Advil Dual Action (ibuprofen + acetaminophen), and Children's Advil. Advil entered the US market in 1984 (the first OTC ibuprofen in America, considered the "most famous prescription-to-OTC switch in history") and generates approximately $800 million+ annually as one of Haleon's flagship brands alongside Sensodyne, Panadol, Centrum, and Theraflu. In September 2024, Advil Dual Action became the first OTC pain reliever to earn the American Dental Association (ADA) Seal of Acceptance for temporary management of acute dental pain.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.